Innovent Expands Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 Alpha-Biased IL-2/PD-1 Bispecific Fusion Protein in Immunotherapy-Resistant NSCLC to Include Non-Squamous Patients

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic…